1-3 of 3
Ying Ou, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies

Ying Ou, PhD, Kun Wang, PhD, Lucy Liu, MBA, Ashutosh Jindal, BS, Yuying Gao, PhD, Sri Sahasranaman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5063.
https://doi.org/10.1182/blood-2019-129580
Published: 2019
Journal Articles

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Srikumar Sahasranaman, PhD, Oleg Demin, Jr., Dmitry Shchelokov, Veronika Musatova, Nageshwar Budha, PhD, Ying Ou, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1289.
https://doi.org/10.1182/blood-2019-129133
Published: 2019
Journal Articles

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, MD, Leonard Klein, MD, Robert M. Rifkin, MD, Priti Patel, MD, MS, Sandra Dixon, MS, Ying Ou, PhD, Alan Cartmell, MD
Journal: Blood
Blood (2013) 122 (21): 1934.
https://doi.org/10.1182/blood.V122.21.1934.1934
Published: 2013